# Ibex Preclinical Research, Inc. – FDA 483, May 22, 2026

Source: https://www.keypedia.com/records/483/ibex-preclinical-research-inc/e14d0449-4777-4992-a2a7-8aee72ebd290

> FDA 483 for Ibex Preclinical Research, Inc. on May 22, 2026. Product: other. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Ibex Preclinical Research, Inc.
- Inspection Date: 2026-05-22
- Product Type: other
- Office Name: Denver District Office
- Summary: Ibex Preclinical Research, Inc. in Logan, UT, was cited for significant deficiencies in its nonclinical laboratory studies, primarily concerning data integrity, protocol adherence, and quality assurance. The inspection revealed failures in accurately recording and verifying experimental data, ensuring proper protocol approval and execution, maintaining adequate standard operating procedures, and managing study archives and final reports. These issues indicate a systemic lack of control over critical aspects of GLP compliance.

## Related Officers

- [issuing_officer](https://www.keypedia.com/people/courtney-r-bratina/3ad4bfd5-d0da-4801-8e90-a5a3ba9291c3)
- [Audrey J. Yarbrough](https://www.keypedia.com/people/audrey-j-yarbrough/1bab3d1a-3246-451e-96fb-4ce52185e850)
- [other](https://www.keypedia.com/people/erin-m-mcdowell/7f3995e6-5596-4b3a-a99b-27d49d4b890e)

Company: https://www.keypedia.com/companies/ibex-preclinical-research-inc/04445709-22a7-4e9d-9fae-6695003020ac

Office: https://www.keypedia.com/offices/denver-district-office/93b79063-390c-4759-af6c-5da7e388face